Differences between genotype 1 patients with SVR or relapse after treatment for chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV)

被引：0
|
作者：
Zehnter, Elmar
Mauss, Stefan
Beoker, Klaus
Thomas, Lutz
Racky, Stefan
Schmidt, Wolfgang
Ullrich, Rainer
Sbrijer, Innessa
Heyne, Renate
Schober, Andreas
John, Christine
Hey, Karl-Heinz
Bokemeyer, Bernd
Kallinowski, Birgit
Moeller, Bernd
Pape, Stefan
Alshuth, Ulrich
Hueppe, Dietrich
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A789 / A789
页数：1
相关论文
共 50 条
  • [21] Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa-2a (40KD)/RBV
    Shobokshi, O
    Serebour, FE
    Skakni, L
    Al-Jasser, N
    Tantawi, AO
    Sabah, A
    Dinish, T
    Al-Quaiz, M
    Qahtani, K
    Sandokji, A
    Al-Blowi, A
    Al-Karawi, M
    Al-Kayyal, B
    Al-Momen, S
    Akbar, H
    Ayoola, A
    El-Hazmi, M
    Humaida, A
    El-Hazmi, I
    Eissa, H
    Khawajah, F
    Al-Khalifa, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 172 - 172
  • [22] PEG-IFN alfa-2a (40KD) (Pegasys) plus amantadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C
    Ideo, G
    Giuseppe, S
    Attili, A
    Chirianni, A
    Craxi, A
    Di Perri, G
    Picciotto, A
    Rizzetto, M
    Ruggiero, G
    Suter, F
    Sarracino, M
    HEPATOLOGY, 2002, 36 (04) : 570A - 570A
  • [23] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [24] Prospective evaluation of peginterferon alfa-2a (40KD)/ribavirin in CHC, IFN/ribavirin nonresponders/relapsers
    Parise, E
    Meirelles, A
    Martinelli, A
    Lacet, C
    Correa, E
    Cotrim, H
    Settee, H
    Cheinquer, H
    Gallizi, J
    Fonseca, J
    Parana, R
    da Silva, R
    Spinelli, V
    Gomes, A
    Crespo, D
    Lima, L
    Pereira, L
    Tiexeira, R
    Amorim, W
    Tatsch, F
    JOURNAL OF HEPATOLOGY, 2003, 38 : 161 - 161
  • [25] Change of Treatment Patterns Over a Decade of Dual Therapy of Chronic Hepatitis C (CHC) With Peginterferon Alfa-2A (PEG) and Ribavirin (RBV)
    Eisenbach, Christoph
    Naumann, Uwe
    Bokemeyer, Bernd
    Pape, Stefan
    Waizmann, Michael
    Isernhagen, Konrad
    Loehr, Hanns
    Steffens, Hermann
    Knechten, Heribert
    Roessle, Martin
    Haessner, Joachim
    Racky, Stefan
    Alshuth, Ulrich
    Buggisch, Peter
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2012, 142 (05) : S957 - S958
  • [26] Ribavirin (RBV) dose reduction in patients with HCV genotype 1 infection receiving combination treatment with peginterferon alfa-2a (40kd) (Pegasys®) plus RBV (Copegus®)
    Lee, JS
    Hu, S
    Lopez-Talavera, JC
    Hoffmann-La Roche, F
    HEPATOLOGY, 2004, 40 (04) : 335A - 335A
  • [27] PHARMACOKINETICS (PK) OF RIBAVIRIN (RBV) IN PATIENTS WITH RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE (ESRD) AND CHRONIC HEPATITIS C (CHC) DURING TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RBV (COPEGUS®)
    Wang, Karen
    Lawal, Adebayo A.
    Majchrowicz, Martin
    Morcos, Peter N.
    Moreira, Sebastian
    Draibe, Sergio A.
    Ghalib, Reem H.
    Zaman, Atif
    Crippin, Jeffrey S.
    Joshi, Virendra
    Martin, Paul
    Grippo, Joseph
    HEPATOLOGY, 2008, 48 (04) : 1142A - 1142A
  • [28] Effect of ethnicity on the pharmacokinetics of ribavirin (COPEGUS®) and peginterferon alfa-2a (40kd) (PEGASYS®) in patients with chronic hepatitis C
    Brennan, B
    Morrison, R
    Hagedorn, C
    Marbury, TC
    Sulkowski, M
    Grippo, J
    Gries, JM
    HEPATOLOGY, 2005, 42 (04) : 652A - 653A
  • [29] Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Foster, Graham R.
    Fried, Michael W.
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Freivogel, Klaus
    Weiland, Ola
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 247 - 255
  • [30] Sustained virological response (SVR) to peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC
    Fargion, S
    Borzio, M
    Maraschi, A
    Cargnel, A
    JOURNAL OF HEPATOLOGY, 2004, 40 : 140 - 140
12345